Lp(a) - pronounced 'L-P-little-a' - is a lipoprotein particle that carries cholesterol in the blood. It is structurally similar to LDL but has an additional protein called apolipoprotein(a) attached to it. That extra protein makes Lp(a) stickier and more prone to depositing in arterial walls, and it also has properties that interfere with normal clot-dissolving. The result is a particle that is independently atherogenic - meaning it raises heart attack and stroke risk above and beyond what your LDL or total cholesterol would predict. Most standard cholesterol panels do not measure it. You have to order it specifically.

Not much, with currently available tools. This is the hardest truth about Lp(a). Diet, exercise, and statins - the main levers people reach for on standard cardiovascular risk factors - have minimal impact on Lp(a). Niacin (high-dose) can reduce Lp(a) by 20-30%, but large trials did not show that this translated into reduced cardiovascular events, and niacin has its own side-effect profile. PCSK9 inhibitors (injectable cholesterol-lowering agents used in high-risk patients) modestly lower Lp(a). RNA-based therapies specifically targeting Lp(a) are in late-stage clinical trials as of 2026 and show substantial reductions in the particle - they are not yet approved. The practical takeaway for someone with elevated Lp(a) today: you cannot easily lower the number itself, so the clinical response is to drive down every other cardiovascular risk factor more aggressively than you otherwise would - LDL, blood pressure, insulin resistance, inflammation, smoking.

Yes, predominantly. Lp(a) levels are largely determined by the LPA gene, which codes for the apolipoprotein(a) component. Estimates from genetic studies suggest that somewhere between 70 and 90 percent of the variation in Lp(a) levels between individuals is heritable. This is why lifestyle changes have so little impact on it - you largely inherited your Lp(a) level. It also means that if you have a parent or sibling with elevated Lp(a), your probability of having it elevated is meaningfully higher. The genetic nature of Lp(a) is why some cardiologists consider a single lifetime measurement sufficient - your number does not drift much over time the way your LDL might with dietary changes.

Cardiovascular biomarkers · Blood panel · Updated May 2026

Lp(a) test: the genetic heart risk you test once

Q: What is a high Lp(a) level?

Reporting units vary, which creates real confusion. In nmol/L (the preferred unit of many cardiovascular researchers and increasingly common on labs): roughly above 75 nmol/L is often cited as elevated in functional-medicine and longevity contexts; above 125 nmol/L corresponds to what large cardiovascular trials have used as a threshold for meaningfully elevated risk. In mg/dL (still used by many US labs): above 30 mg/dL is commonly flagged as elevated, with above 50 mg/dL considered high risk by many guidelines. These cutoffs are debated - there is no single universally agreed threshold. The pattern that matters: the higher your Lp(a), the greater your independent cardiovascular risk, and the more aggressively the rest of your cardiovascular profile needs to be managed. A result of 200 nmol/L is a different clinical picture than 80 nmol/L, even if both are 'elevated.' Discuss your specific number with a clinician in the context of your full cardiovascular picture.

Q: What is the difference between Lp(a) in nmol/L and mg/dL?

The two units measure different things and cannot be directly converted with a simple fixed multiplier, which is a genuine source of confusion. nmol/L measures the number of Lp(a) particles. mg/dL measures the mass of Lp(a) protein. The reason a fixed conversion does not work is that the size of the apolipoprotein(a) component varies person to person (it is genetically determined), so the same number of particles can have different masses in different people. Many cardiovascular researchers prefer nmol/L because it measures particles directly. If your lab reports in mg/dL, a rough commonly cited approximation is that 30 mg/dL is approximately 75 nmol/L, but treat this as an approximation only. Ask your lab which unit they use, and compare any follow-up tests in the same unit.

Lp(a) is a lipoprotein particle that raises your risk of heart attack and stroke independently of LDL. It is largely genetic, does not respond to diet or statins, and for most people the clinical standard is to measure it once in your life. If your number is elevated, the way you manage cardiovascular health shifts from that day. Most doctors never order it. Here is what you need to know.

See the full cardiovascular blood panel guide ->

The direct answer

Lp(a) - lipoprotein little-a - is a cholesterol-carrying particle in your blood that independently raises cardiovascular risk. It is about 70 to 90 percent genetically determined, which means diet and exercise move it very little. The standard recommendation is to measure it once in adulthood. If your level comes back below roughly 75 nmol/L (or below 30 mg/dL on older unit reporting), most clinicians consider that a low-risk result and do not revisit it. If it comes back elevated - particularly above 125 nmol/L or 50 mg/dL - the clinical picture changes: you treat LDL, blood pressure, and every other modifiable cardiovascular risk factor more aggressively than you otherwise would, because the Lp(a) burden is not going anywhere.

The frustrating truth is that there is currently no approved drug that reliably lowers Lp(a) to the extent you can lower LDL. RNA-targeting therapies in late-stage trials look promising as of 2026, but they are not yet available. So knowing your number matters not because you can directly treat it today, but because it changes how hard you work on everything else.

What Lp(a) actually is - and why your standard cholesterol panel misses it

A standard lipid panel measures total cholesterol, LDL, HDL, and triglycerides. It does not measure Lp(a). You have to ask for it specifically, which means a large share of adults with elevated Lp(a) have no idea.

Structurally, Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) attached. That protein has two effects that matter for cardiovascular risk. First, it makes the particle stickier - more prone to adhering to arterial walls and depositing there. Second, apolipoprotein(a) has structural similarity to plasminogen, a protein involved in breaking down clots. That structural mimicry means elevated Lp(a) can interfere with normal clot dissolution. The combination - increased arterial deposition plus impaired clot clearance - is why elevated Lp(a) is an independent risk factor for heart attack and stroke, not just a companion risk that rides alongside high LDL.

The genetic story is important to understand. The gene responsible for producing apolipoprotein(a) is called LPA, and the version you inherited largely determines your Lp(a) level. Studies in large twin cohorts and family datasets consistently place the heritability of Lp(a) between 70 and 90 percent. This is substantially higher than the heritability of LDL or triglycerides. Your Lp(a) is mostly your genetic starting point, not a reflection of how well you have been eating or exercising.

Reference ranges and optimal targets - both, with context

One genuine source of confusion is that Lp(a) is reported in two different units by different labs, and they are not directly interchangeable with a simple multiplier.

Category	nmol/L (preferred unit)	mg/dL (still common in US)
Standard lab reference range	Below 75 nmol/L (commonly cited acceptable range)	Below 30 mg/dL (commonly cited acceptable range)
Longevity-optimal target	Below 50 nmol/L (lower is generally better; no lower threshold of concern)	Below 20 mg/dL (rough approximation - use nmol/L if possible)
Elevated - manage CV risk more aggressively	Above 75 nmol/L	Above 30 mg/dL
High - significantly elevated risk	Above 125 nmol/L (threshold used in major CV outcomes research)	Above 50 mg/dL

Important caveat on these numbers: the longevity-optimal targets above are functional-medicine goals - more aggressive than the population reference ranges, and not universal medical consensus. The exact cutoffs are debated across cardiology guidelines. There is no universally agreed threshold at which Lp(a) suddenly becomes dangerous; risk increases continuously with the level. Use these numbers to orient yourself, not to self-diagnose. Discuss your specific result with a clinician in the context of your full cardiovascular profile.

The unit issue deserves its own note. The reason nmol/L and mg/dL do not convert with a simple multiplier is that apolipoprotein(a) varies in size between individuals - it is genetically determined and affects the mass per particle. If your lab reports in mg/dL, a rough approximation sometimes used is that 30 mg/dL corresponds to approximately 75 nmol/L - but treat this as a rough guide only. If you ever retest, use the same unit and the same lab for comparison.

How often to test Lp(a) - and why once is usually enough

The current clinical standard from major cardiology societies is that a single lifetime measurement is sufficient for most adults. This is unusual in medicine, where most biomarkers are tracked repeatedly because they change in response to lifestyle or treatment.

Lp(a) is different because it does not change much. Across adult life, individual Lp(a) levels are remarkably stable - studies tracking people over years show minimal drift. The main things that can cause meaningful variation are hormonal states (pregnancy, postmenopause, thyroid dysfunction) and acute illness, but even these effects are usually modest. The practical upshot: if you tested Lp(a) five years ago and were not pregnant or acutely ill at the time, that number is likely still representative.

When should you retest? There are a few scenarios where a second measurement makes sense. First, if your first test was done during a period of significant illness, pregnancy, or active thyroid disease. Second, if you are enrolling in a longevity clinic or cardiovascular risk management program and want a clean baseline under those specific lab conditions. Third, if you are enrolled in a clinical trial for an Lp(a)-targeting therapy where tracking your particle level is part of the protocol. Otherwise, measure it once, know your number, and move on to managing the risk factors you can actually change.

What to do if your Lp(a) is elevated

This is the question that actually matters. The answer is not "take a supplement." The answer is a shift in how aggressively you manage everything else.

Lower LDL harder

Elevated Lp(a) is an additive cardiovascular risk factor. Carrying both elevated Lp(a) and elevated LDL multiplies risk more than either alone. If your Lp(a) is high, the LDL target your cardiologist aims for gets lower. The commonly cited threshold for cardiovascular risk management in people with elevated Lp(a) is an LDL below 70 mg/dL - more aggressive than the under-100 target that might apply in a lower-risk person. Statins do not lower Lp(a) (and in some people modestly raise it), but they lower LDL effectively and remain an important tool in the overall CV risk picture.

Control blood pressure tightly

Hypertension combined with elevated Lp(a) accelerates the arterial damage that Lp(a) drives. A systolic pressure below 120 mmHg is increasingly the longevity-medicine target - more aggressive than the traditional under-130 threshold. For someone carrying elevated Lp(a), this is not a nice-to-have.

Manage insulin resistance and inflammation

Lp(a) is more dangerous in the context of arterial inflammation and metabolic dysfunction. High fasting glucose, high insulin, and elevated inflammatory markers like hsCRP all amplify the risk that elevated Lp(a) carries. Getting insulin sensitivity under control through diet, exercise, and sleep is not going to move your Lp(a) number, but it can substantially change the cardiovascular terrain that Lp(a) operates in.

Aspirin - a nuanced conversation

Low-dose aspirin's role in primary cardiovascular prevention has been revised significantly in recent years; current guidelines have largely moved away from recommending it for average-risk adults due to bleeding risk. For someone with elevated Lp(a) and other significant cardiovascular risk factors, the risk-benefit calculus looks different. This is a decision to make with a physician who knows your full picture - not a self-treatment call.

What about drugs that lower Lp(a)?

PCSK9 inhibitors (injectable cholesterol-lowering agents used in high-risk patients who cannot achieve LDL targets on statins) can lower Lp(a) by roughly 15 to 30 percent as a secondary effect. They are approved for LDL management, not specifically for Lp(a), and access typically requires significant LDL elevation and specialist involvement. High-dose niacin lowered Lp(a) in studies but did not reduce cardiovascular events in large trials and is rarely used now. RNA-based therapies (antisense oligonucleotides and small interfering RNA) that specifically target the LPA gene are showing reductions in Lp(a) of 70 to 90 percent in late-stage trials as of 2026. They are not yet FDA-approved for Lp(a) specifically. Watch this space - this is the most likely near-term change in how elevated Lp(a) is managed.

Family history and who should get tested

Because Lp(a) is largely genetic, family history is the strongest indicator of whether to prioritize testing. Large cardiovascular outcome studies show that people with a first-degree relative (parent or sibling) with a heart attack or stroke before age 60 have substantially higher probability of carrying elevated Lp(a). If your family history looks like this, getting your Lp(a) measured is a straightforward first step.

Beyond family history, Lp(a) testing is worth considering if you have had a cardiovascular event (heart attack or stroke) with otherwise unremarkable traditional risk factors - elevated Lp(a) often explains cases of heart disease in people whose LDL, blood pressure, and lifestyle do not seem to justify it. It is also a reasonable add-on any time you are getting a comprehensive cardiovascular panel done.

The practical answer to "should I test this?": if you have never measured it, yes. It is a single blood draw, available at most labs, and the result either tells you your risk is not elevated or gives you information that should change how aggressively you manage your cardiovascular health for the rest of your life. The asymmetry between the cost of the test and the value of knowing is clear.

Where to get the test and how it fits your broader panel

Lp(a) is a single add-on lab order. Most physicians can order it alongside a standard lipid panel, though many do not include it by default - you may need to ask specifically. Direct-to-consumer lab services (Quest, LabCorp, Ulta Lab Tests) allow you to order it without a physician order in most states. Comprehensive longevity panels at services like Ageless and Superpower typically include Lp(a) as part of their cardiovascular risk workup.

One note on interpretation: Lp(a) is most useful in context, not isolation. Knowing your Lp(a) is elevated means the most when you also know your LDL, ApoB, hsCRP, blood pressure, blood glucose, and family history. That full picture is what a clinician needs to help you build the right cardiovascular management approach. If you are building a complete baseline, see the cardiovascular blood panel guide for the full marker set worth tracking.

We do not currently have a lab-testing affiliate partner. The services named above are mentioned because they are real and commonly used - we earn no commission on them. If you want bloodwork bundled with medical oversight and a longevity protocol, see the longevity Rx matrix - services like Ageless order panels at intake and interpret them in clinical context.

From the Editor

What I would tell my dad about Lp(a): get it measured once, and do it soon. This is one of those tests where the downside of not knowing is worse than the discomfort of knowing. If it comes back fine - below 50 or 75 nmol/L - you file the result, stop worrying about it, and focus on the things that move more easily with effort (LDL, blood pressure, insulin). If it comes back elevated, nothing changes about your routine today, but everything changes about how hard you push on those other levers from here.

The frustrating part is that most primary care doctors do not order this test routinely. It is not on the standard metabolic panel. It is not on the standard lipid panel. You have to know to ask for it - and most men do not know to ask. That is a gap in the system that costs real people real outcomes. The test is cheap. The particle it measures is one of the stronger genetic predictors of early cardiovascular disease. The failure mode here is not being too aggressive about testing; it is the default passivity of only measuring what the annual physical already includes.

If your dad has never had his Lp(a) measured, and especially if there is heart disease or early stroke anywhere in your family history, this is the one ask worth making at his next appointment. One draw, one result, one piece of the picture that should be in every man's file by 50.

Frequently asked questions

What is Lp(a)?

Lp(a) - pronounced "L-P-little-a" - is a lipoprotein particle that carries cholesterol in the blood. It is structurally similar to LDL but with an additional protein called apolipoprotein(a) attached. That extra protein makes Lp(a) stickier and more prone to depositing in arterial walls, and it has properties that interfere with normal clot-dissolving. The result is a particle that is independently atherogenic - it raises heart attack and stroke risk above and beyond what your LDL or total cholesterol would predict. Most standard cholesterol panels do not measure it. You have to order it specifically.

How often do you test Lp(a)?

For most adults, once in a lifetime is the clinical standard recommendation. Lp(a) is largely genetically determined and remains stable throughout adult life. It does not fluctuate meaningfully with diet, exercise, or most medications the way LDL or triglycerides do. The reason to test it is to establish your baseline risk category - elevated or not - and then incorporate that information into your long-term cardiovascular management. If you have never had it measured, get it measured once and know your number.

What is a high Lp(a) level?

Above roughly 75 nmol/L is often cited as elevated in functional-medicine and longevity contexts. Above 125 nmol/L corresponds to what large cardiovascular trials have used as a threshold for meaningfully elevated risk. In mg/dL: above 30 mg/dL is commonly flagged as elevated, with above 50 mg/dL considered high risk by many guidelines. These cutoffs are debated - there is no single universally agreed threshold. The higher your Lp(a), the greater your independent cardiovascular risk, and the more aggressively the rest of your cardiovascular profile needs to be managed. Discuss your specific number with a clinician in context of your full cardiovascular picture.

Can you lower Lp(a)?

Not much, with currently available tools. Diet, exercise, and statins have minimal impact on Lp(a). Niacin can reduce it by 20 to 30 percent but large trials did not show that this translated into fewer cardiovascular events. PCSK9 inhibitors modestly lower Lp(a) as a secondary effect. RNA-based therapies specifically targeting Lp(a) are in late-stage clinical trials as of 2026 and show substantial reductions - they are not yet approved. The practical takeaway for someone with elevated Lp(a) today: drive down every other cardiovascular risk factor more aggressively than you otherwise would, because the Lp(a) burden is not going anywhere soon.

What is the difference between Lp(a) in nmol/L and mg/dL?

nmol/L measures the number of Lp(a) particles. mg/dL measures the mass of Lp(a) protein. The reason a fixed conversion does not work is that the size of the apolipoprotein(a) component varies person to person (it is genetically determined), so the same number of particles can have different masses in different people. Many cardiovascular researchers prefer nmol/L because it measures particles directly. A rough commonly cited approximation is that 30 mg/dL is approximately 75 nmol/L - treat this as an approximation only. Compare any follow-up tests in the same unit from the same lab.

Is Lp(a) genetic?

Yes, predominantly. Lp(a) levels are largely determined by the LPA gene, which codes for the apolipoprotein(a) component. Genetic studies estimate that 70 to 90 percent of the variation in Lp(a) levels between individuals is heritable. This is why lifestyle changes have so little impact on it - you largely inherited your Lp(a) level. If you have a parent or sibling with elevated Lp(a) or early cardiovascular disease, your probability of having elevated Lp(a) is meaningfully higher than average.

How we make money on this page

We have no lab-testing affiliate partner and earn nothing if you order an Lp(a) test anywhere. If you use Ageless or another longevity telehealth service reached via our longevity Rx matrix, we may earn a commission - at no cost to you. Full disclosure.

Where to go next

Cardiovascular blood panel guide - the full set of markers worth tracking for heart and vascular health: ApoB, Lp(a), hsCRP, homocysteine, LP-PLA2, and more
ApoB optimal range - ApoB is the particle count that many longevity cardiologists now treat as the primary LDL target; if your Lp(a) is elevated, ApoB is the companion number to drive down hard
Best longevity Rx telehealth - if you want bloodwork ordered under medical supervision with clinical interpretation, this is the matrix; Ageless and others include Lp(a) in their cardiovascular intake panels
Semaglutide and cardiovascular health - if your elevated Lp(a) sits alongside metabolic risk factors, semaglutide's cardiovascular outcome data is relevant context
Protocol One FAQ - common questions about how to read lab results and what to do with them

Last reviewed - 2026-05-31